ATLAS study: A randomized double-blind phase 3 study of adjuvant axitinib versus placebo in subjects at high risk of recurrent renal cell carcinoma (RCC).

Authors
Category Primary study
Conference50th American Society of Clinical Oncology (ASCO) Annual Meeting; 2014 May 30-Jun 3; Chicago, IL, United States. Journal of Clinical Oncology
Year 2014
This article has no abstract
Epistemonikos ID: 6bb032ec446bfddb50ffcd14f033df89ef60f555
First added on: Jun 24, 2020